The company is focused on the clinical development and commercial exploitation through partnering of its highly innovative antimicrobial drugs and has an open door policy to discussing potential business relationships. These range from partnering and licensing through to investment and non-dilutive funding as well as risk sharing and joint ventures with industry, academia and governments.
Please contact us at email@example.com to start a discussion.
The company has already completed one collaboration with China Medical Systems signed in 2017 who have rights to the XF platform for Greater China and related territories.
- Destiny Pharma to present at LSX World Congress 2020, 4th February 2020, London, UK 07/01/2020
- Destiny Pharma to present at JPM / Biotech Showcase 2020, 13 – 15 January 2020, San Francisco, USA 07/01/2020
- Destiny Pharma to present at BFC Global Healthcare Investment Conference, 12 January 2020, San Francisco, USA 07/01/2020